Menu
Recruiting NCT05729932

Cannabis and Opioid Use Disorder

Phase I Interventional Opioid Use Disorder

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Inhaled vaporized cannabis, Intransal opioid.
Who it may be relevant to
Registry conditions: Opioid Use Disorder. Basic parameters: 18 years — 55 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Cannabis Modulation of Outcomes Related to Opioid Use Disorder: Opioid Withdrawal, Abuse Potential and Safety

Overview

This study plans to enroll participants with opioid use disorder who are not currently seeking treatment to assess the effects of cannabis on opioid withdrawal and other related outcomes.

Interventions

  • Drug Inhaled vaporized cannabis
    Double-blind cannabis and placebo doses, administered through vaporizer
  • Drug Intransal opioid
    Double-blind opioid and placebo doses, administered intranasal route

Primary outcome measures

  • Change from Baseline - Opioid Withdrawal Severity - Visual Analog Scale (VAS) [Time frame: Change from baseline]
Secondary outcome measures (2)
  • Change from Baseline - Opioid Drug Liking - Visual Analog Scale (VAS) [Time frame: Change from baseline]
  • Change from Baseline - Respiration [Time frame: Change from baseline]

Eligibility criteria

Inclusion criteria

  • Current opioid use disorder

Exclusion criteria

  • Current medical conditions that require medical management

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Triple blind
Primary purpose
Basic science

Study locations

United States · 1 center
  • Center on Drug and Alcohol Research — Lexington

Identifiers

NCT: NCT05729932 · 75562-20242 · 1R01DA054347

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗